We are live on
!
Find out more
AA
AlphaCentric Advisors Portfolio holdings
AUM
$100M
This Fund
S&P 500
This Quarter
Est. Return
+9.61%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$149M
AUM Growth
-$27.3M
(-16%)
Cap. Flow
-$34.7M
Cap. Flow
% of AUM
-23.28%
Top 10 Holdings %
Top 10 Hldgs %
25.17%
Holding
298
New
63
Increased
40
Reduced
80
Closed
82
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ABVX
Abivax
ABVX
|
+$2.73M |
| 2 |
Pfizer
PFE
|
+$2.42M |
| 3 |
argenx
ARGX
|
+$2.33M |
| 4 |
VYNE Therapeutics
VYNE
|
+$2.08M |
| 5 |
Invesco NASDAQ 100 ETF
QQQM
|
+$1.95M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Neurocrine Biosciences
NBIX
|
+$3.38M |
| 2 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$2.95M |
| 3 |
iShares 1-3 Year Treasury Bond ETF
SHY
|
+$2.75M |
| 4 |
TSVT
2seventy bio
TSVT
|
+$2.58M |
| 5 |
Crinetics Pharmaceuticals
CRNX
|
+$2.44M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 59.47% |
| 2 | Real Estate | 11.94% |
| 3 | Financials | 4.93% |
| 4 | Consumer Discretionary | 2.41% |
| 5 | Industrials | 2.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
76
Vanguard High Dividend Yield ETF
VYM
$80B
| $375K | 0.25% |
3,358
+664
| +25% | +$69.8K |
|
77
iShares Mortgage Real Estate ETF
REM
$559M
| $372K | 0.25% |
15,777
-1,069
| -6% | -$23.6K |
|
78
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.6B
| $372K | 0.25% |
4,174
+771
| +23% | +$64.9K |
|
79
State Street SPDR S&P International Dividend ETF
DWX
$525M
| $370K | 0.25% |
10,417
-1,407
| -12% | -$47.5K |
|
80
iShares JPMorgan EM High Yield Bond ETF
EMHY
$613M
| $369K | 0.25% |
10,152
-1,544
| -13% | -$53.4K |
|
81
Pultegroup
PHM
$24B
| $367K | 0.25% |
3,553
+778
| +28% | +$66.1K |
|
82
iShares Preferred and Income Securities ETF
PFF
$13.3B
| $365K | 0.24% |
11,691
+2,256
| +24% | +$67.4K |
|
83
Invesco Senior Loan ETF
BKLN
$7.19B
| $363K | 0.24% |
17,151
-2,107
| -11% | -$44.2K |
|
84
Invesco S&P 500 BuyWrite ETF
PBP
$348M
| $363K | 0.24% |
16,719
-1,718
| -9% | -$36.8K |
|
85
Delta Air Lines
DAL
$55.4B
| $362K | 0.24% |
8,991
+3,779
| +73% | +$137K |
|
|
VALN
86
Valneva
VALN
$511M
| $353K | 0.24% |
34,298
+13,708
| +67% | +$157K |
|
|
NARI
87
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $325K | 0.22% |
+5,000
| New | +$301K |
|
88
United Airlines
UAL
$37.5B
| $320K | 0.21% |
7,758
+1,961
| +34% | +$77.1K |
|
89
Loews
L
$23.6B
| $309K | 0.21% |
+4,444
| New | +$295K |
|
|
SAFE
90
Safehold
SAFE
$1.22B
| $280K | 0.19% |
11,972
| – | – |
|
91
United Rentals
URI
$65.5B
| $276K | 0.19% |
+482
| New | +$227K |
|
92
MGM Resorts International
MGM
$11.8B
| $265K | 0.18% |
5,942
+1,283
| +28% | +$50.3K |
|
93
Everest Group
EG
$15.1B
| $259K | 0.17% |
733
+446
| +155% | +$173K |
|
94
Arch Capital
ACGL
$35.4B
| $253K | 0.17% |
3,402
+2,196
| +182% | +$179K |
|
|
DPRO
95
Draganfly
DPRO
$155M
| $240K | 0.16% |
20,000
| – | – |
|
|
CBAY
96
DELISTED
Cymabay Therapeutics
CBAY
| $236K | 0.16% |
10,000
-5,000
| -33% | -$89K |
|
97
Costco
COST
$417B
| $221K | 0.15% |
+335
| New | +$199K |
|
98
Broadridge
BR
$17.3B
| $220K | 0.15% |
+1,069
| New | +$197K |
|
99
Ford
F
$56.7B
| $214K | 0.14% |
17,534
+8,333
| +91% | +$92.7K |
|
100
Hartford Financial Services
HIG
$38.4B
| $212K | 0.14% |
2,637
+1,141
| +76% | +$85.9K |
|
Similar funds
WCM
FCM
BIA
AGAM
E
HCM
AC
OIS
AlphaCentric Advisors's Q4 2023 Portfolio in Review
As of Q4 2023, AlphaCentric Advisors held 298 positions worth $149M, down 16% from $176M the previous quarter. Its ten largest holdings account for 25% of the portfolio.
AlphaCentric Advisors withdrew a net $34.7M in Q4 2023, closing 82 positions and reducing 80 holdings. Its most notable exit was Neurocrine Biosciences, an estimated $3.38M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 59% of assets, down from 62% a quarter earlier, followed by Real Estate and Financials.
Against the trend, AlphaCentric Advisors opened a new position in Abivax worth $2.86M.
- AlphaCentric Advisors's largest Q4 2023 buy was Abivax: 267,500 shares worth $2.86M.
- AlphaCentric Advisors added most to argenx in Q4 2023, an estimated $2.33M increase.
- AlphaCentric Advisors's biggest Q4 2023 reduction was iShares 1-3 Year Treasury Bond ETF, cutting an estimated $2.75M.
- AlphaCentric Advisors fully exited Neurocrine Biosciences in Q4 2023, selling an estimated $3.38M.
- AlphaCentric Advisors's ten largest holdings make up 25% of its $149M portfolio in Q4 2023.
- AlphaCentric Advisors opened 63 new positions and closed 82 in Q4 2023.
- AlphaCentric Advisors's portfolio value fell 16% quarter-over-quarter to $149M.
Based on AlphaCentric Advisors's 13F filing for Q4 2023, filed 14 Feb 2024.